What is the difference between the Turkish version of Abatacept and the domestic version?

The Turkish version of Abatacept (Abatacept) is not much different from the domestic version of Abatacept. Both were developed by the U.S. pharmaceutical company Bristol-Myers Squibb. After approval by the U.S. Food and Drug Administration (FDA), it was exported to various countries. The trade name is Orencia. Abatacept is a drug that is often used in combination with methotrexate. Abatacept available in China is an imported drug with the same ingredients, and there may be differences in its price.

Patients with moderately to severely active rheumatoid arthritis who are being treated with methotrexate when other drugs including methotrexate or "tumor necrosis factor (TNF) blockers" are not effective; with methotrexate Pterin combination for use in adult patients with highly active and progressive rheumatoid arthritis who have not been previously treated with methotrexate; or for use in adolescents and children over 2 years of age with moderately to severely active polyarticular juvenile idiopathic arthritis who have not responded well to other drugs.用其他药物治疗效果不佳的成人银屑病关节炎也可以使用阿巴西普进行治疗。

The original abatacept drug on the domestic market has not yet entered the scope of medical insurance through the relevant policies of the National Medical Insurance Bureau. It is a strictly controlled drug, and its purchase channels are restricted. It must be used by doctors or medical staff. It is a prefilled syringe with specifications of 125mg (0.95ml)*4. The price per box may be more than 6,000 yuan. The price of each box of the Turkish version of abatacept original drug sold overseas may be more than more than 3,000 yuan, and the price of each box of the European version may be more than 10,000 yuan (the price may fluctuate due to exchange rates).